%0 Journal Article
%@ 2369-1999
%I JMIR Publications
%V 7
%N 3
%P e26574
%T Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study
%A Veldhuijzen,Evalien
%A Walraven,Iris
%A Belderbos,José
%+ Department of Radiation Oncology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, Netherlands, 31 020 512 9111, j.belderbos@nki.nl
%K PRO-CTCAE
%K lung cancer
%K side effects
%K patient-reported outcomes
%K PROM
%K symptomatic adverse events
%D 2021
%7 14.9.2021
%9 Original Paper
%J JMIR Cancer
%G English
%X Background: The Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library covers a wide range of symptoms relevant to oncology care. There is a need to select a subset of items relevant to specific patient populations to enable the implementation of PRO-CTCAE–based symptom monitoring in clinical practice. Objective: The aim of this study is to develop a PRO-CTCAE–based subset relevant to patients with lung cancer that can be used for monitoring during multidisciplinary clinical practice. Methods: The PRO-CTCAE–based subset for patients with lung cancer was generated using a mixed methods approach based on the European Organization for Research and Treatment of Cancer guidelines for developing questionnaires, comprising a literature review and semistructured interviews with both patients with lung cancer and health care practitioners (HCPs). Both patients and HCPs were queried on the relevance and impact of all PRO-CTCAE items. The results were summarized, and after a final round of expert review, a selection of clinically relevant items for patients with lung cancer was made. Results: A heterogeneous group of patients with lung cancer (n=25) from different treatment modalities and HCPs (n=22) participated in the study. A final list of eight relevant PRO-CTCAE items was created: decreased appetite, cough, shortness of breath, fatigue, constipation, nausea, sadness, and pain (general). Conclusions: On the basis of the literature and both professional and patient input, a subset of PRO-CTCAE items has been identified for use in patients with lung cancer in clinical practice. Future work is needed to confirm the validity and effectiveness of this PRO-CTCAE–based lung cancer subset internationally and in real-world clinical practice settings. 
%M 34519658
%R 10.2196/26574
%U https://cancer.jmir.org/2021/3/e26574
%U https://doi.org/10.2196/26574
%U http://www.ncbi.nlm.nih.gov/pubmed/34519658